{
    "links": "https://www.ycombinator.com/companies/synkrino-biotherapeutics",
    "name": "Synkrino Biotherapeutics",
    "headline": "Synkrino's AI, SATIS is a powerful, unbiased discovery system for\u00e2\u0080\u00a6",
    "batch": "S18",
    "description": null,
    "activity_status": "Active",
    "website": "http://www.synkrino.bio",
    "founded_date": null,
    "team_size": 2.0,
    "location": "Oakland, CA",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:ai-powered-drug-discovery; industry:biotech; location:san-francisco-bay-area",
    "founders": [],
    "status": true,
    "generated_description": "**Synkrino Biotherapeutics Overview**\n\nSynkrino Biotherapeutics is an innovative biotech company located in Oakland, California. As part of the Y Combinator Batch S18, Synkrino leverages artificial intelligence to enhance biotherapeutics development. Their flagship AI system, SATIS, aims to revolutionize drug discovery by providing an unbiased and powerful framework for identifying potential therapeutic solutions.\n\n**Mission**\n\nThe core mission of Synkrino is to advance drug discovery through their AI platform, which promises to streamline and optimize the often complex process of developing new drugs. They position themselves at the intersection of AI and biopharmaceuticals, focusing on making the discovery phase both more effective and efficient.\n\n**Team and Structure**\n\nDespite being a small operation with a team of just two employees, Synkrino is poised for significant impact in the biotech sector. Their agility allows them to navigate the rapidly evolving landscape of drug discovery with a focus on innovation.\n\n**Community and Focus Areas**\n\nSynkrino is tagged as a key player in the areas of AI-powered drug discovery and biotech within the San Francisco Bay Area ecosystem. This region is known for its vibrant tech and biotech communities, creating a fertile ground for collaboration and growth.\n\n**Final Thoughts**\n\nWhile the company is still in its early stages, the potential for Synkrino Biotherapeutics to make waves in the biotech field is undoubtedly promising. By harnessing the power of AI, they aim to break new ground in the discovery of life-saving therapies. If you\u2019re interested in cutting-edge biotherapeutics and AI, keeping an eye on Synkrino could be worthwhile.",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/730c9fde4fb0a01bdd15913a66ecf30192692921.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAKBB576US%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T192002Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJHMEUCIFRjVxB%2FHxIJHUHkMazoRi02jYmaJVJGr3K7C9j9jiflAiEA6iszI4%2Fpn8hDzk7aMP6LlnqynbPgCG20CpdZqslTFdsq7gMI3P%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAAGgwwMDYyMDE4MTEwNzIiDNVC6v4lNMvTlUOjTyrCA7R4NjcD6pWk9Gjux5NdrMhwU67pNo%2F0JVDzkHcTjBsajnWXpXoyD3m%2FssX0rwYmnUDJB9VTgD%2FW2M8cWxeD93WFxLjs25juzzGj1%2BC1Ky9E0oNPwn5jGw%2BjokWylkxcouU18mjUtP8juH4uF9Xfmm%2FMAgvOPsNSAaYBQ%2BdA5Vwom66MCzynAPEJs6Nqxd5FqtgiiWFRhT5L9g%2FvfLTKqpdIg0XPF6s95lLCtwWDHST72Bn9JVH2zZmqjTgO2sao7Rg4M%2BPIRazg8JhbPoWk6xsB2yfG1f%2Bs8AFVxihyUnQj6TUnhrhezs7WYsaTfaaAoTIzhEsLwJDqBQDSptmSlUj%2BQ3KWwrXpJIm0b1uOmaylnrEpn5obECdRc%2FzdEfNt6DNEE5cbUhQo8Gjfd6MWfyV7JHtX7DwsLMssQPKNZ6qWJq2gP1fVHFkz5K0F%2F73p54AKB5gCkyOeRPJHmAzYMdfZpMF%2B8hE4eZU6k7m1EqPLEW2F9HVvcqPFp8T%2BZgbbDLBVWICSdX%2FfJ%2BniwyC72aHLaqjCxHLvJ6WyAawaepaDD9csEvz4DYD9lpHx9hJXqrFDyrT1vAaaBwuoXgulZ6gNmjCmiuO9BjqlATnnhPFnQUT7QmhXwrAFbGCqdgkRFIVCdDrNmasZJtz86frmIpB%2BlwZjavL0FMq46mN9RKFTuRNdMnOtOh1adMI%2BkC%2F%2Bs3m8pwR56JxErG%2B8nIBe7efeu5WiUZbGCsp85oXBCGY%2FoP1uWrJo843L0LVdmjtyXaDurxXSgzfeZo2RDONME7LNkPzuGzA19XefIc9OvA1QFcZr3VIdZe%2BLywfFgDpgwA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=bc15e9223a6493d1ef6d3bbbeb61b6b469d283173576edcbf0da6564aeb2c0db",
    "social_links": [],
    "logo_path": "data/logos\\Synkrino_Biotherapeutics_logo.png"
}